#United States #Irvine #JUVÉDERM #Allergan Aesthetics #SKINVIVE

Allergan Aesthetics Gains FDA Approval for SKINVIVE by JUVÉDERM®

On June 16, 2026, Allergan Aesthetics, a subsidiary of AbbVie, announced that it has received approval from the U.S. Food and Drug Administration (FDA) for SKINVIVE by JUVÉDERM®. This injectable treatment is designed to improve the appearance of neck lines, particularly those caused by factors like aging, sun exposure, weight loss, and notably, 'tech-neck', a condition developed by prolonged head-down smartphone usage.

SKINVIVE by JUVÉDERM® becomes the first hyaluronic acid (HA) injectable to effectively address these neck wrinkles, marking a significant innovation in aesthetics. This treatment works by helping the skin retain its moisture, enhancing both softness and smoothness of the neck area. Patients treated with SKINVIVE can expect minimal complications and downtime. The injectable, which can be administered through an ultrafine needle or a cannula, includes a small amount of the local anesthetic lidocaine to ensure comfort during the procedure. The aesthetic effects typically last for about six months, although patients might require touch-ups for optimal results.

The approval expands Allergan Aesthetics’ portfolio of transformative options for lower-face and neck treatments, offering aesthetic providers and patients a unique method to enhance neck appearance. Darin Messina, Ph.D., the Senior Vice President of Aesthetics R&D at AbbVie, commented on the approval, highlighting Allergan's ongoing commitment to deliver groundbreaking innovations that fulfill significant unmet needs in the aesthetic market.

In a pivotal clinical study evaluating SKINVIVE by JUVÉDERM®, about 74.8% of the trial participants exhibited a clinically significant improvement in neck lines after one month of treatment, and a substantial number retained this progress after six months. Most reported side effects were mild and typically subsided within two weeks, making it a generally safe option for individuals seeking improvements in neck aesthetics.

With this new approval, Allergan Aesthetics has established a protocol that mandates training for all practitioners before they can administer SKINVIVE. This approach ensures that patients receive the treatment from well-informed professionals, maximizing safety and effectiveness. The company expects that SKINVIVE will be available commercially later this year, allowing more patients to benefit from this innovative product.

As clinical studies continue to support the efficacy and safety of SKINVIVE by JUVÉDERM®, users can stay informed about the product and its availability by visiting www.skinvive.com or following the brand's updates on social media platforms. As the aesthetic field evolves, products like SKINVIVE represent a shift towards more advanced, minimally invasive procedures that cater to modern aesthetic concerns, reflecting societal shifts in how we perceive aging and beauty.

Conclusion

By receiving FDA approval for SKINVIVE by JUVÉDERM®, Allergan Aesthetics positions itself as a leader in addressing neck aesthetics. This treatment promises to bridge the gap in cosmetic solutions for neck lines, turning complex aesthetic needs into achievable outcomes. The implications of this innovation extend beyond just cosmetic enhancement; they encompass a broader understanding of patient care and the constant pursuit of improved quality of life through aesthetic interventions.

With a focus on comfort, effectiveness, and minimal invasiveness, SKINVIVE by JUVÉDERM® stands as a testament to the advancements in aesthetic medicine, ensuring that everyone can feel confident in their skin.

For additional information regarding safety and treatment guidelines, refer to the official product information available through Allergan Aesthetics.